MA43871A - INHIBITION OF B-CELL LYMPHOMA 2 (BCL -2) AND RELATED PROTEINS - Google Patents
INHIBITION OF B-CELL LYMPHOMA 2 (BCL -2) AND RELATED PROTEINSInfo
- Publication number
- MA43871A MA43871A MA043871A MA43871A MA43871A MA 43871 A MA43871 A MA 43871A MA 043871 A MA043871 A MA 043871A MA 43871 A MA43871 A MA 43871A MA 43871 A MA43871 A MA 43871A
- Authority
- MA
- Morocco
- Prior art keywords
- bcl
- inhibition
- cell lymphoma
- related proteins
- proteins
- Prior art date
Links
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 title 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 title 1
- 208000003950 B-cell lymphoma Diseases 0.000 title 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277248P | 2016-01-11 | 2016-01-11 | |
| US201762444168P | 2017-01-09 | 2017-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43871A true MA43871A (en) | 2018-11-21 |
Family
ID=59312078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043871A MA43871A (en) | 2016-01-11 | 2017-01-11 | INHIBITION OF B-CELL LYMPHOMA 2 (BCL -2) AND RELATED PROTEINS |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3402485A1 (en) |
| JP (1) | JP2019501225A (en) |
| AU (1) | AU2017206731A1 (en) |
| MA (1) | MA43871A (en) |
| WO (1) | WO2017123616A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019207608B2 (en) | 2018-01-10 | 2024-03-28 | Recurium Ip Holdings, Llc | Benzamide compounds |
| CN110143941B (en) * | 2019-06-04 | 2021-05-25 | 北京四环制药有限公司 | Synthesis method of intermediate of balusavir mefene |
| TW202116319A (en) * | 2019-07-10 | 2021-05-01 | 美商瑞卡瑞恩Ｉｐ控股有限責任公司 | Nanoparticle formulation of bcl-2 inhibitor |
| CN114786654A (en) * | 2019-12-11 | 2022-07-22 | 密执安大学评议会 | Compositions and methods for systemic delivery of Bcl-2 and Bcl-xL antagonists |
| EP4370099A1 (en) * | 2021-07-16 | 2024-05-22 | Celator Pharmaceuticals, Inc. | Methods for preparing liposomal formulations |
| WO2024012557A1 (en) * | 2022-07-15 | 2024-01-18 | Berrybio (Hong Kong) Limited | Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5043164A (en) * | 1989-01-17 | 1991-08-27 | The University Of Tennessee Research Corporation | Blood-stable, cholesterol-free liposomes |
| KR101376895B1 (en) * | 2004-05-03 | 2014-03-25 | 헤르메스 바이오사이언스, 인코포레이티드 | Liposomes useful for drug delivery |
| PT1888550E (en) * | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Apoptosis promoters |
| CN101534904B (en) * | 2006-09-05 | 2013-11-06 | Abbvie公司 | BCL inhibitors treating platelet excess |
| BR112012005343A2 (en) * | 2009-09-10 | 2016-03-22 | Novartis Ag | sulfonamides as bcl-2 family protein inhibitors for cancer treatment |
-
2017
- 2017-01-11 JP JP2018554661A patent/JP2019501225A/en active Pending
- 2017-01-11 MA MA043871A patent/MA43871A/en unknown
- 2017-01-11 AU AU2017206731A patent/AU2017206731A1/en not_active Abandoned
- 2017-01-11 EP EP17738848.5A patent/EP3402485A1/en not_active Withdrawn
- 2017-01-11 WO PCT/US2017/012992 patent/WO2017123616A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019501225A (en) | 2019-01-17 |
| EP3402485A1 (en) | 2018-11-21 |
| WO2017123616A1 (en) | 2017-07-20 |
| AU2017206731A1 (en) | 2018-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43871A (en) | INHIBITION OF B-CELL LYMPHOMA 2 (BCL -2) AND RELATED PROTEINS | |
| MA50860A (en) | CHEMERICAL RECEPTERS OF ANTIGEN AGAINST B-CELL MATURATION ANTIGEN AND CODING POLYNUCLEOTIDES | |
| DK3478811T3 (en) | Cleaning compositions and uses thereof | |
| MA42819A (en) | METHODS FOR THE TREATMENT OF ARENAVIRIDAE AND CORONAVIRIDAE VIRAL INFECTIONS | |
| DK3578547T3 (en) | SULPHONYLURASES AND RELATED COMPOUNDS AND USE OF THE SAME | |
| DK3368069T3 (en) | USE OF MYOSTATINI INHIBITORS AND COMBINATION THERAPIES | |
| DK3595653T3 (en) | COMPOSITIONS OF PLINABULIN AND USE THEREOF | |
| MA44990A (en) | POLYTHERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS | |
| MA46427A (en) | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES | |
| MA46566A (en) | OXYSTEROLS AND THEIR METHODS OF USE | |
| MA45270A (en) | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES | |
| JP2018172409A5 (en) | Compositions comprising 15-HEPE and methods of using same | |
| DK3672976T3 (en) | BCL-2 INHIBITORS | |
| MA51306A (en) | IMPROVED COMPOSITIONS AND METHODS FOR THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY | |
| MA53506A (en) | METHODS OF CANCER TREATMENT WITH SMALL MOLECULE PD-L1 INHIBITORS | |
| IL279475A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| DK3430129T5 (en) | COLONY-FORMING MEDIUM AND USE THEREOF | |
| DK3543240T3 (en) | URAT1 inhibitor and use thereof | |
| DK3302549T3 (en) | Combination treatment of an anti-CD20 antibody with a Bcl-2 inhibitor and an MDM2 inhibitor | |
| DK3576738T3 (en) | GABOXADOL MONOHYDRATE IN THE TREATMENT OF TINNITUS | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| DK3474883T3 (en) | COMPLEMENT INHIBITORS AND USES THEREOF | |
| DK3697405T3 (en) | NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | |
| DK3102218T3 (en) | TREATMENT OF TOPIC AND SYSTEMIC BACTERIA INFECTIONS | |
| IL282533A (en) | Oligosaccharide compositions and methods of use thereof |